Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock

Chicago Capital added 969,592 shares of PROCEPT BioRobotics in Q1 2026, an estimated $27.32 million purchase that lifted its stake to 2,160,587 shares valued at $54.04 million. The position now equals 1.46% of the fund's $3.71 billion AUM, suggesting continued conviction despite PRCT's 56.5% year-over-year share decline. The article frames the buying as a bet on improving fundamentals and long-term growth in urologic robotics, but the immediate market impact should be limited.

Analysis

The important signal is not the headline size of the buy, but that a sophisticated allocator is continuing to average down into a name that remains deeply discounted despite improving unit economics. That usually indicates conviction that the market is still pricing PRCT as a single-product commercialization risk when the real debate is whether it can sustain procedure growth long enough for operating leverage to matter. If that thesis is right, the stock can re-rate quickly because medtech growth names often move on inflection in installed base and recurring revenue visibility, not on current earnings.

The second-order winner is the broader urology ecosystem: hospitals and surgeons adopting PRCT tend to create inertia around disposable revenue streams, service contracts, and training pathways, which makes the installed base more valuable over time. The competitive risk is that larger medtech incumbents can tolerate a longer payback period and use distribution advantages to pressure adoption, so PRCT’s moat depends on procedure-level superiority staying clearly differentiated. Any signal that peer products or alternative BPH therapies are closing the efficacy gap would hit the multiple harder than a modest miss on quarterly revenue.

Near term, the stock is still a sentiment trade, not a fundamentals trade. Over the next 1-2 quarters, the key catalysts are procedure growth acceleration, reimbursement commentary, and evidence that international adoption is not just anecdotal. The main tail risk is a financing overhang or slowing capital equipment purchases if hospital budgets tighten, which would compress growth expectations before earnings ever turn positive.

Consensus is probably underestimating how much bad news is already embedded after a >50% drawdown and how much incremental upside can come from simply proving durability. The market may also be treating the recurring revenue mix as optionality, when in practice it can become the primary valuation anchor once the installed base scales. That creates asymmetric upside if growth persists, because the stock can rerate from "unprofitable device story" to "recurring-enabled platform" well before GAAP profitability arrives.

Key Decisions for Investors

• Long PRCT on weakness over the next 2-6 weeks, but size modestly: the setup is asymmetric if procedure growth holds, yet execution risk remains high; target 25-40% upside on a 12-month view, with a hard stop if growth indicators decelerate two quarters in a row.
• Buy PRCT call spreads 3-6 months out rather than stock if you want convexity: the name can re-rate sharply on positive adoption data, but options cap downside if hospital spending or reimbursement sentiment worsens.
• Pair long PRCT vs short a basket of slower-growth, lower-dispersion medtech names over 1-3 months: this expresses the view that the market is rewarding differentiated procedure platforms over mature device franchises.
• Avoid chasing after large green days; prefer entries after broad biotech/medtech de-risks or following any pullback tied to macro tape, since the thesis depends on idiosyncratic adoption data rather than factor momentum.
• For risk-controlled exposure, use a starter position only and add on evidence of sustained procedure growth or international traction; if those catalysts fail, thesis duration extends into years and capital should be redeployed.